Is Bioxytran, Inc. (BIXT) a Buy, Sell, or Hold?
OTC : BIXT
Bioxytran, Inc. — News
$0.0214 USD
$0.0 (-18.63%)
- Volume
- 31.9K
- Average Volume
- 88.81K
- Market Capitalization
- $2.12M
- P/E Ratio
- -0.81
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.09
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.09
| Source | Headline |
|---|---|
|
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota's Department of Chemistry to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets. globenewswire.com - 2026-08-04 07:00:00 |
|
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, July 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (the "Company"), a clinical-stage biotechnology company developing therapeutics in based on carbohydrate chemistry, galectin antagonism, and oxygen transport, today announced the publication of a sponsored corporate research report by Globe Small Cap Research. The report Research Bioxytran as a multi-platform biotechnology story built around carbohydrate science, galectin antagonism, and oxygen-transport therapeutics, with active programs spanning antiviral therapy, stroke and hypoxia, and an emerging commercial bridge through the Company's A-SUQAR dietary supplement. globenewswire.com - 2026-07-29 07:00:00 |
|
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25. The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the book introduces the concept of “Physiological Mapping,” a unique methodology designed to monitor tissue metabolism and oxygenation in vivo and in real-time. globenewswire.com - 2026-05-29 08:03:00 |
|
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25. globenewswire.com - 2026-05-29 08:03:00 |
